Drug Profile

RN 1201

Alternative Names: RN-1201

Latest Information Update: 27 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AlloRunning Therapeutics; Rui Therapeutics
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

11 Aug 2025 AlloRunning Therapeutics in collaboration with Tianjin Medical University plans a phase I trial for Multiple myeloma (First line therapy) in China (Parenteral; Infusion) (NCT07114432)
06 Aug 2025 Preclinical trials in Autoimmune disorders in China (IV)
06 Aug 2025 Rui Therapeutics and AlloRunning Therapeutics plans a phase I trial for Autoimmune disorders (Treatment experienced) in China in August 2025 (NCT07105735)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com